Podcasts about BTK

Tanner Dannish, a regular on BTK and the owner and founder of Frontiersmen Gear, returns for a breakdown of the Ram Awards that will be part of the Wild Sheep Society of BC's convention schedule for 2026.  With an eye towards hunting heritage and a clear conservation ethos behind the awards being presented, Tanner unpacks why he felt it was important to bring these awards back to the BC mountain hunting community and how they're different from many of the awards given out at other conventions.  Later in the show, the topic of failure and what makes a hunt a truly successful hunt is debated.  NOTABLE QUOTES:  "When you look at the quality of animals that we have and the amount of hunting you can do here in BC, it's a very special place, so we're trying to honour that."  @wildsheepsocietybc  @frontiersmengear  LINK TO AWARDS SUBMISSIONS AND NOMINATIONS  REGISTER FOR THE 2026 MOUNTAIN HUNTING EXPO  REGISTER FOR THE 2026 NORTHERN FUNDRAISER   ---------------------------  DEALS & PARTNERS:  For over 100 years Leica has set the standard for premium optics. From spotting scopes to binoculars, rifle scopes and the new CRF MAX rangefinders, Leica is the choice for those who accept no compromises.  Don't miss out on Canada's best mountain hunting and conservation expo! The 2026 Wild Sheep Society of BC's Salute to Conservation Mountain Hunting Expo will sell out fast. Get your tickets now!  onX Hunt is the most powerful 3D mapping solution for hunters. Get your FREE trial today. If you're already a member, check out the exclusive offers and perks available when you upgrade to an Elite Member.   Tired of gut rotting instant coffee? Check out This Is Coffee and get yourself some great instant coffee for when you're in the backcountry or on the road.  ---------------------------  SUPPORT WILD SHEEP:  Go to Wild Sheep Foundation to find a membership option that suits your budget and commitment to wild sheep.  Go to Wild Sheep Society of BC to become a member, enter raffles, buy merch and support BC's wild sheep populations.  SUPPORT MOUNTAIN GOATS:  Go to Rocky Mountain Goat Alliance to find a membership option that suits your budget and commitment to conserving mountain goats and their habitat.   

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to highlight chronic lymphocytic leukemia (CLL) updates from the 2025 ASH Annual Meeting. Drs Armstrong and Tawagi noted that CLL is typically diagnosed in asymptomatic, elderly individuals presenting with lymphocytosis. A definitive diagnosis is established by confirming the clonality of circulating B lymphocytes via immunoglobulin light chain restriction on flow cytometry, they explained. Treatment initiation is reserved for active disease, which is indicated by B symptoms, progressive cytopenias, threatened organ function, or bulky disease such as splenomegaly, they said. They continued by reporting several prognostic features that denote poor outcomes. Current standard frontline regimens use covalent BTK inhibitors or time-limited targeted regimens that include venetoclax (Venclexta), often combined with an anti-CD20 monoclonal antibody, according to the experts. They added that TKI-based therapy is preferred for patients with high-risk features. The phase 3 BRUIN CLL-313 trial (NCT05023980) investigated pirtobrutinib (Jaypirca), a highly selective noncovalent BTK inhibitor, compared with bendamustine and rituximab (BR) in patients with treatment-naive CLL. The trial showed a significant improvement in progression-free survival with pirtobrutinib vs BR. Pirtobrutinib was also associated with a favorable safety profile, with modest rates of class-associated toxicities, including all-grade bleeding, arthralgia, and atrial fibrillation. Although pirtobrutinib showed superior efficacy in BRUIN CLL-313, the clinical interpretation of these data is complicated because BR is an outdated control arm compared with contemporary frontline standards, Armstrong and Tawagi emphasized. Furthermore, the requirement for indefinite therapy with BTK inhibitors is a sequencing challenge, particularly as pirtobrutinib is currently approved in the post-covalent BTK inhibitor setting, they continued. However, its favorable toxicity profile suggests potential utility in elderly patients with pre-existing cardiovascular comorbidities, they noted. Future studies are focused on comparing pirtobrutinib vs time-limited venetoclax and evaluating various triplet regimens, they concluded.

Welcome back to our BTK/ASGBI Series! During this series, BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam compare and contrast various aspects of surgery between the United States and the United Kingdom, debating who does what better.  We are happy to be continuing our AI discussion further with another episode. While last episode lay a foundation on discussing the unique differences in the role and regulation of AI in both these countries, now we delve into some of the clinical challenges. What does AI and the future of surgery look like in underserved locations such as the battlefield or the rural communities. What does this mean for our future as surgeons…will we be replaced? And how should we address the integration of AI within our practices?  We are thrilled to have our trio of experts discussing this further. Dr. Nelson is a surgical oncologist working at the Brook Army Medical Center in San Antonio, he's very interested in expanding the role of AI within surgical education and beyond. Dr. Larson is a general surgery resident at the Mayo Clinic. She's currently in her research time and finishing up her master's degree in AI and studying the role of machine learning within surgical practice. Dr. Mukherjee is a surgeon scientist alongside an Honorary Consultant General & Major Trauma Surgeon in Liverpool, England. His current research bridges academia with industry and is aimed at transforming the treatment of critical illness through the development of next-generation therapies for pancreatitis-induced acute lung injury through the utilisation of cutting-edge AI driven drug discovery approaches.  Take a listen and let us know what you think!  References: Johns' Hopkins Ex-Vivo Cholecystectomy by a Robot https://hub.jhu.edu/2025/07/09/robot-performs-first-realistic-surgery-without-human-help/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Welcome back to our BTK/ASGBI Series! During this series, BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam compare and contrast various aspects of surgery between the United States and the United Kingdom, debating who does what better.  In this episode, we delve into all things artificial intelligence (AI) within surgery. Both the US and the UK have unique approaches to managing AI within healthcare and our experts help break down these key similarities and differences. We will discuss what AI and machine learning means, what does regulation look like in both these regions, and how is AI being used in both these countries.  We are fortunate to have two representatives, Dr. Nelson and Dr. Larson, representing the US side. Dr. Nelson is a surgical oncologist working at the Brook Army Medical Center in San Antonio, he's very interested in expanding the role of AI within surgical education and beyond. Dr. Larson is a general surgery resident at the Mayo Clinic. She's currently in her research time and finishing up her master's degree in AI and studying the role of machine learning within surgical practice. We are fortunate to have Dr. Mukherjee representing the UK side. Dr. Mukherjee is a surgeon scientist alongside an Honorary Consultant General & Major Trauma Surgeon in Liverpool, England. He has a strong track record in research that spans the translational spectrum, with strengths in discovery science related to acute pancreatitis pathophysiology and mitochondrial injury, novel in vitro and in vivo experimental assay development and clinical translational research, including novel biomarker studies and clinical trials. He has won multiple awards, most recently the Hunterian Professorship 2024 from the Royal College of Surgeons of England. Take a listen and let us know what you think- what do you think is the best way to promote and regulate AI within healthcare?  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Unpacking MS Progression and BTK Inhibitors - Episode 194 In this episode, we will have honest and hopeful conversation about two of the biggest topics in multiple sclerosis today, progression and the next major frontier in treatment: BTK inhibitors. They unpack what makes BTK inhibitors so unique, how they work inside immune cells and the brain, and why they could represent a game-changing step in the MS community. We will also explore how to recognize signs of MS progression, tell the difference between true disease worsening and deconditioning, and have more meaningful conversations with your care team about changes you're noticing. Whether you're living with MS, caring for someone who is, or following the latest research, this episode will leave you informed, empowered, and hopeful about what's ahead. Disclaimer: This podcast provides general educational information. Can Do MS does not endorse, promote, or recommend any product or service associated with the content of this program

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative events shaping the future of drug development, patient care, and global healthcare strategies.**Johnson & Johnson's Multiple Myeloma Advances** Johnson & Johnson has made significant strides in the treatment of multiple myeloma with their bispecific antibody, Tecvayli. In recent trials, Tecvayli has shown remarkable promise when used in combination therapies as a second-line treatment. This development is noteworthy as it could potentially challenge the dominance of CAR-T cell therapies like J&J's Carvykti by offering a more accessible and less complex alternative. For patients, this means potentially fewer logistical hurdles and a more straightforward therapeutic option, which could drastically improve patient care standards.**Regulatory Scrutiny on RSV Vaccines** Turning to regulatory news, the U.S. FDA has intensified its scrutiny of respiratory syncytial virus (RSV) vaccines developed by pharmaceutical giants such as Merck, AstraZeneca, and Sanofi for infants. This increased oversight follows reports linking some COVID-19 vaccines to adverse effects in children. The FDA's actions highlight the ongoing necessity for vigilant safety monitoring in vaccine development, especially for vulnerable populations like infants. This is a crucial step in ensuring that vaccines designed for our youngest population are both safe and effective.**Eli Lilly's Strategic Moves in Oncology and Beyond** Eli Lilly is making waves in oncology with its BTK inhibitor, Jaypirca. Despite strong phase 3 results that support its use as a first-line treatment for chronic lymphocytic leukemia (CLL), Lilly is focusing on its application as a second-line therapy. This strategic choice reflects an astute understanding of market dynamics and therapeutic niches where Jaypirca can provide substantial benefits despite competition from established first-line treatments. Additionally, Eli Lilly continues to leverage its financial success from its weight loss drug Tirzepatide to position itself as a central player in global pharmaceutical innovation. The company's strategic investments are likely to catalyze advancements across various therapeutic areas, reinforcing its role as a key contributor to medical breakthroughs.**Legislative Impact on Biopharma** In legislative news, the Biosecure Act's incorporation into the U.S. National Defense Authorization Act marks a strategic shift towards tightening regulations on Chinese biopharma entities regarding federal contracts by 2026. This move could have profound implications for international collaborations and competition within biotechnology innovation and drug development sectors. It signals a broader trend of increased scrutiny on foreign entities in sensitive industries like biopharmaceuticals.**China's Healthcare Transformation** China's healthcare landscape is undergoing significant transformation with the inclusion of drugs from companies like Pfizer, Lilly, and J&J into its first private insurance formulary. This development could enhance access to innovative medications within China, potentially improving health outcomes and influencing global pricing strategies in the pharmaceutical industry.**Gamida Cell's Milestone in Cell Therapies** In a major milestone for cell therapies, Gamida Cell has secured a second FDA approval for its stem cell therapy Omisirge. Initially approved to reduce infection risk during hematopoietic stem cell transplantations in blood cancer patients, Omisirge's expanded indication to treat severe aplastic anemia underscores the potential of cell therapies in addressing diverse hematologic conditions.**CSL Seqirus' New Facility in Australia** In Australia, CSL Seqirus has opened a $1 billion facility dedicated to producing cell-baSupport the show

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.

Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.

Bryan Kohberger and Dennis Rader (aka BTK) share some similar connections with the main one being Katherine Ramsland who is a well respected criminologist who literally wrote the book on the BTK as well as being Bryan's professor at DeSales University.In this episode, we hear from BTK's daughter Kerri Rawson about her feelings when she first heard about the murders in moscow and where BTK fits in to all of this.(commercial at 7:37)to contact me:bobbycapucci@protonmail.comsource:BTK killer Dennis Rader shares sympathy for Idaho murders suspect Bryan Kohberger | The IndependentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Netflix has released a documentary profiling what it is like to be the child of an infamous serial killer, the daughter of the BTK killer. We often hear about these cases from the 70s and 80s, but rarely today, is there a big serial killer captured. Has technology caught up with them? Are serial killers a dying population? And why are we so fascinated by them? Joining Anton to discuss is Clinical and Forensic Psychologist and Director of Forensic Psychological Services, Dr Patrick Randall.

In 1974, Wichita, Kansas was shaken by a series of brutal attacks inside family homes. Men, women, and children were bound, tortured, and killed by a predator who called himself BTK. For 17 years, he terrorized the community, claiming at least 10 victims and taunting police with disturbing letters that detailed his crimes. Then in 1991, the killings abruptly stopped, leaving law enforcement and the public to wonder if the killer had vanished forever. For more than a decade, there was silence. Then in 2004, BTK resurfaced with new messages, reigniting fear in Wichita. But that renewed need for attention would ultimately be his downfall, and by the following year, detectives had identified the killer as Dennis Rader, a father of two, a Scout leader, and a trusted member of his church council. Rader was the last person anyone suspected of being a sexual sadist serial killer, but once investigators began putting all the puzzle pieces together, it became clear that Rader's family-man persona was just a mask covering the monster beneath. Try our coffee!! - www.CriminalCoffeeCo.com Become a Patreon member -- > https://www.patreon.com/CrimeWeekly Shop for your Crime Weekly gear here --> https://crimeweeklypodcast.com/shop Youtube: https://www.youtube.com/c/CrimeWeeklyPodcast Website: CrimeWeeklyPodcast.com Instagram: @CrimeWeeklyPod Twitter: @CrimeWeeklyPod Facebook: @CrimeWeeklyPod ADS: 1. https://www.HelloFresh.com/CrimeWeekly10FM - Get 10 FREE meals and FREE breakfast for LIFE! 2. https://www.Incogni.com/CrimeWeekly - Use code CRIMEWEEKLY for 60% off! 3. https://www.HelixSleep.com/CrimeWeekly - Get 27% off sitewide NOW! 4. https://www.EatIQBAR.com - Text WEEKLY to 64000 for 20% off ALL IQBAR products and FREE shipping! 5. https://www.Rula.com/CrimeWeekly - Make your mental health your top priority today with Rula! Let them know we sent you!

After killing Marine Hedge in 1985 and Vicki Wegerle in 1986, Dennis Rader vanished into suburban normalcy for almost twenty years—leading Cub Scouts, serving as church president, and installing home alarms for terrified neighbors. While the task force chased ghosts, he privately curated scrapbooks and fantasized about new victims. In 2004, stung by a newspaper article implying BTK had died or lost his nerve, Rader resurfaced with letters, crime-scene photos, and a floppy disk he believed was untraceable. Digital metadata and his own daughter's DNA ended the longest cat-and-mouse game in Kansas history, exposing the monster who had hidden in plain sight all along. - Sources:https://docs.google.com/document/d/1eTYeCoYyxm58DXXdoFbHQyWHlWbcH9iKGIefFcQToW4/edit?tab=t.0 Listen to our new show, "THE CONSPIRACY FILES"!: -Spotify - https://open.spotify.com/show/5IY9nWD2MYDzlSYP48nRPl -Apple Podcasts - https://podcasts.apple.com/us/podcast/the-conspiracy-files/id1752719844 -Amazon/Audible - https://music.amazon.com/podcasts/ab1ade99-740c-46ae-8028-b2cf41eabf58/the-conspiracy-files -Pandora - https://www.pandora.com/podcast/the-conspiracy-files/PC:1001089101 -iHeart - https://iheart.com/podcast/186907423/ -PocketCast - https://pca.st/dpdyrcca -CastBox - https://castbox.fm/channel/id6193084?country=us - Stay Connected: Join the Murder in America fam in our free Facebook Community for a behind-the-scenes look, more insights and current events in the true crime world: https://www.facebook.com/groups/4365229996855701 If you want even more Murder in America bonus content, including ad-free episodes, come join us on Patreon: https://www.patreon.com/murderinamerica Instagram: http://instagram.com/murderinamerica/ Facebook:https://www.facebook.com/people/Murder-in-America-Podcast/100086268848682/ Twitter: https://twitter.com/MurderInAmerica TikTok: https://www.tiktok.com/@theparanormalfiles and https://www.tiktok.com/@courtneybrowen Feeling spooky? Follow Colin as he travels state to state (and even country to country!) investigating claims of extreme paranormal activity and visiting famous haunted locations on The Paranormal Files Official Channel: https://www.youtube.com/c/TheParanormalFilesOfficialChannel - (c) BLOOD IN THE SINK PRODUCTIONS 2025 Learn more about your ad choices. Visit megaphone.fm/adchoices

Dennis Rader a sévi de 1974 à 1991 à Wichita aux Etats-Unis où il tue 10 personnes âgées de 9 à 62 ans. Il se fait appeler BTK pour « Bind, Torture, and Kill »… Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dennis Rader a sévi de 1974 à 1991 à Wichita aux Etats-Unis où il tue 10 personnes âgées de 9 à 62 ans. Il se fait appeler BTK pour « Bind, Torture, and Kill »… Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, the landscape of the pharmaceutical and biotech industries is marked by groundbreaking scientific advancements, regulatory shifts, and strategic collaborations that promise to reshape patient care and drug development significantly.A controversy has emerged in the wake of proposed changes to U.S. vaccine regulations by Dr. Vinay Prasad, a senior FDA official. This proposal has sparked considerable opposition from 12 former FDA commissioners who argue that these regulatory overhauls could potentially undermine public trust in vaccines. Former leaders from both the CDC and FDA have expressed concerns over these proposed vaccine policy changes during an ACIP meeting, discussions that could influence future public health strategies and vaccine trust. At a time when vaccine confidence is crucial, maintaining the integrity of regulatory processes is vital to public health efforts.Leadership changes are also afoot within the FDA, as Dr. Tracy Beth Hoeg steps into the role of acting director for the Center for Drug Evaluation and Research. Her appointment signals a shift towards leaders with direct experience in public health crises. This comes amidst further internal restructuring at the FDA, including the transfer of Theresa Michele, long-standing director of the Office of Nonprescription Drugs, indicating dynamic changes within the agency.In the realm of oncology, Eli Lilly's progress with its Bruton's tyrosine kinase inhibitor, Jaypirca, is noteworthy. The drug's expanded label now includes earlier treatment stages for chronic lymphocytic leukemia and small lymphocytic lymphoma. This expansion underscores the therapeutic potential of non-covalent BTK inhibitors and may significantly improve patient outcomes by offering earlier intervention options.Geopolitical challenges are impacting the industry as WuXi AppTec, a major China-based biopharmaceutical contractor, faces scrutiny from the Pentagon amid concerns about its potential ties with the Chinese military. This development highlights the complex interplay between global security concerns and international biotech collaborations. The intersection of global security concerns continues to impact biopharmaceutical supply chains as WuXi AppTec faces increased scrutiny from U.S. authorities.On the manufacturing front, Quvara Medical's emergence as a new contract development and manufacturing organization following Buckland Group's acquisition of a Becton Dickinson facility in the UK reflects industry trends toward consolidating manufacturing capabilities to meet growing biopharmaceutical demand efficiently.AstraZeneca is enhancing its pipeline through a renewed partnership with Neurimmune for an amyloidosis asset. This collaboration, potentially worth up to $780 million, highlights AstraZeneca's strategic focus on rare diseases and underscores their commitment to expanding their therapeutic portfolio through successful alliances.Regulatory updates from the FDA propose reductions in user fees for early-stage clinical trials conducted domestically while considering additional fees for overseas developments. This initiative aims to incentivize research activities within the U.S., potentially accelerating drug discovery timelines and fostering domestic innovation.In surgical technology advancements, Medtronic's Hugo surgical robot has secured FDA clearance for procedures involving prostate, kidney, and bladder removal. This marks a significant advancement in robotic-assisted surgeries and could enhance patient outcomes across approximately 230,000 surgeries annually in the U.S.As we explore more about financial maneuvers within this sector, Royalty Pharma's $275 million financing deal for Denali Therapeutics' Hunter syndrome drug reflects confidence in Denali's pipeline pendinSupport the show

Beginning in the late 1970s, Ruth Finley was terrorized by a mysterious stalker known as 'The Poet'. At that time, Wichita, Kansas, was on the hunt to find another monster: the BTK serial killer. Over time, Ruth's encounters with The Poet grew more violent, leading investigators to ask a chilling question: was Ruth yet another victim on BTK's list, or did Wichita have another serial predator on the loose? Associate Professor of English at Baruch College, CUNY, Corey Mead discusses the many twists and turns in the case, as well as the shocking conclusion, as detailed in his new book, The Pursued. Follow Emily on Instagram: @realemilycompagno If you have a story or topic we should feature on the FOX True Crime Podcast, send us an email at: truecrimepodcast@fox.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

#282: Israel Keyes schlendert vorbei an seinen Bücherregalen, sein Blick schweift über die Bücher voller dunkler Sehnsüchte und Fantasien. Seine Bibliothek der Serienmörder. Ted Bundy. James Mitchell DeBardeleben. Dennis Rader, bekannt als BTK. Israel Keyes hat ihre Geschichten nicht nur gelesen, er hat sie regelrecht studiert. Aus Bewunderung und kalter Berechnung: Was haben sie falsch gemacht? Wo sind sie aufgeflogen? Wie kann er es besser machen? Mit zwei Gläsern Wein in der Hand wendet er sich von seiner Bibliothek ab und geht durch den Flur, bis er die Tür zu einem Raum öffnet – dorthin, wo sein nächstes Opfer geknebelt liegt. Bald, so denkt er, wird er zur Riege seiner Vorbilder gehören. Doch sein Name wird nicht gleichen Atemzug wie ihre genannt werden. Denn er will besser sein. Ein Perfektionist des Grauens. Der Beste. Eine Produktion von Auf Ex Productions. Hosts: Leonie Bartsch, Linn Schütze Recherche: Linn Schütze, Maike Frye Redaktion: Antonia Fischer Produktion: Lorenz Schütze Quellen (Auswahl) Buch “American Predator: The hunt for the most meticulous serial killer of the 21th century” von Maureen Callahan Buch “Der nomadische Teufel: die wahre Geschichte von Israel Keyes, Amerikas systematischstem Serienmörder, der überall in den USA Mordverstecke anlegte” von Genoveva Ortiz Buch “Devil in the Darkness, the true story of serial killer Israel Keyes” von JT Hunter Dokumentation ZDF Artikel [stern Crime](https://www.stern.de/panorama/verbrechen/stern-crime/fallgeschichten/israel-keyes---der-perfektionist-unter-den-serienmoerdern-9376286.html) Website [FBI](https://www.fbi.gov/news/stories/new-information-released-in-serial-killer-case) Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/MordaufEx) Du möchtest Werbung in diesem Podcast schalten? [**Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio!**](https://www.seven.one/portfolio/sevenone-audio)

In 1974, Wichita, Kansas was shaken by a series of brutal attacks inside family homes. Men, women, and children were bound, tortured, and killed by a predator who called himself BTK. For 17 years, he terrorized the community, claiming at least 10 victims and taunting police with disturbing letters that detailed his crimes. Then in 1991, the killings abruptly stopped, leaving law enforcement and the public to wonder if the killer had vanished forever. For more than a decade, there was silence. Then in 2004, BTK resurfaced with new messages, reigniting fear in Wichita. But that renewed need for attention would ultimately be his downfall, and by the following year, detectives had identified the killer as Dennis Rader, a father of two, a Scout leader, and a trusted member of his church council. Rader was the last person anyone suspected of being a sexual sadist serial killer, but once investigators began putting all the puzzle pieces together, it became clear that Rader's family-man persona was just a mask covering the monster beneath. Try our coffee!! - www.CriminalCoffeeCo.com Become a Patreon member -- > https://www.patreon.com/CrimeWeekly Shop for your Crime Weekly gear here --> https://crimeweeklypodcast.com/shop Youtube: https://www.youtube.com/c/CrimeWeeklyPodcast Website: CrimeWeeklyPodcast.com Instagram: @CrimeWeeklyPod Twitter: @CrimeWeeklyPod Facebook: @CrimeWeeklyPod ADS: 1. https://www.PDSDebt.com/CrimeWeekly - Get your FREE assessment and find the best option for you at PDS Debt! 2. https://www.EatIQBAR.com - Text WEEKLY to 64000 for 20% off ALL IQBAR products and FREE shipping! 3. https://www.Coyuchi.com/CrimeWeekly - Get 20% off your first order with Coyuchi! 4. https://www.Smalls.com/CrimeWeekly - Get 60% off your first order plus FREE shipping with Smalls! 5. https://www.SmartCredit.com/CrimeWeekly - Start your 7-day trial with Smart Credit for just $1!

Before he became the nightmare of Wichita, Kansas – the sadistic serial killer who taunted police with letters signed “BTK” – Dennis Rader was just a quiet, unassuming boy growing up in middle America. In this chilling episode, we go back to the beginning. This is the origin story of one of America's most infamous serial killers – the story of how Dennis Rader spent decades carefully constructing the perfect mask… This is the making of BTK. - Listen to our new show, "THE CONSPIRACY FILES"!: -Spotify - https://open.spotify.com/show/5IY9nWD2MYDzlSYP48nRPl -Apple Podcasts - https://podcasts.apple.com/us/podcast/the-conspiracy-files/id1752719844 -Amazon/Audible - https://music.amazon.com/podcasts/ab1ade99-740c-46ae-8028-b2cf41eabf58/the-conspiracy-files -Pandora - https://www.pandora.com/podcast/the-conspiracy-files/PC:1001089101 -iHeart - https://iheart.com/podcast/186907423/ -PocketCast - https://pca.st/dpdyrcca -CastBox - https://castbox.fm/channel/id6193084?country=us - Stay Connected: Join the Murder in America fam in our free Facebook Community for a behind-the-scenes look, more insights and current events in the true crime world: https://www.facebook.com/groups/4365229996855701 If you want even more Murder in America bonus content, including ad-free episodes, come join us on Patreon: https://www.patreon.com/murderinamerica Instagram: http://instagram.com/murderinamerica/ Facebook:https://www.facebook.com/people/Murder-in-America-Podcast/100086268848682/ Twitter: https://twitter.com/MurderInAmerica TikTok: https://www.tiktok.com/@theparanormalfiles and https://www.tiktok.com/@courtneybrowen Feeling spooky? Follow Colin as he travels state to state (and even country to country!) investigating claims of extreme paranormal activity and visiting famous haunted locations on The Paranormal Files Official Channel: https://www.youtube.com/c/TheParanormalFilesOfficialChannel - (c) BLOOD IN THE SINK PRODUCTIONS 2025 Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a preview for the 25th episode of the Patreon-exclusive show Resolved. To access the rest of this episode - as well as the other bonus material available to supporters of Unresolved Productions - head on over to Patreon and help support this show. To learn more: https://www.patreon.com/posts/btk-part-four-144020123Become a supporter of this podcast: https://www.spreaker.com/podcast/unresolved--3266604/support.

SPONSORS: - Sign up for a $1 per month trial period at https://shopify.com/bears - If you're 21 or older, get 40% OFF your first order + free shipping @‌IndaCloud with code BEARS at https://inda.shop/BEARS ! #indacloudpod - Head to https://DRINKAG1.com/BEARS to get a FREE Welcome Kit with an AG1 Flavor Sampler and a bottle of Vitamin D3 plus K2, when you first subscribe! - Our listeners get 10% off their first month at https://betterhelp.com/bears ‌ Tom Segura returns to the cave with the one-and-only Kirk Fox, comedian, actor, and possibly a future Supermax inmate, depending on how you interpret this episode. The two dive into Kirk's accidental tennis-career-turned-acting path, his eccentric family upbringing (outdoor showers, blood-written memorials, and a grandma in a box), and his lifelong dream of becoming either an FBI profiler or a serial killer — whichever opportunity arrives first. From Waymo self-driving cars acting like drunk Uber drivers to territorial pissings, choke etiquette, BTK, Tommy Lynn Sells, Vince Champ the stand-up sex criminal, and a full breakdown of Supermax prison life, this episode spirals into a darkly hilarious masterclass on murder, consent, and why prison might actually be relaxing if you need more sleep. If the FBI is listening — it's all jokes. Probably. 2 Bears, 1 Cave Ep. 315 https://tomsegura.com/tour https://www.bertbertbert.com/tour https://store.ymhstudios.com Chapters 00:00:00 - Intro 00:01:34 - Tennis Legend Kirk Fox 00:08:40 - Charo Looks Like Bon Jovi 00:11:20 - Kirk's Home Life 00:17:53 - Golden Showers 00:24:46 - More Killers & AI Sex Robots 00:33:42 - Tommy Lynn Sells & Killing by Train 00:37:43 - The Next Killer in Our Friend Group 00:40:49 - Supermax Prison Fantasy 00:46:29 - My Dad Was A Serial Killer 00:52:38 - Vince Champ: The Sex Crime Comedian 00:58:21 - Kirk's FBI Dreams & Shamelessness 01:02:22 - Kirk & Tom Check Out Vince Champ's Comedy 01:06:07 - See You In Prison Learn more about your ad choices. Visit megaphone.fm/adchoices

In 1974, Wichita, Kansas was shaken by a series of brutal attacks inside family homes. Men, women, and children were bound, tortured, and killed by a predator who called himself BTK. For 17 years, he terrorized the community, claiming at least 10 victims and taunting police with disturbing letters that detailed his crimes. Then in 1991, the killings abruptly stopped, leaving law enforcement and the public to wonder if the killer had vanished forever. For more than a decade, there was silence. Then in 2004, BTK resurfaced with new messages, reigniting fear in Wichita. But that renewed need for attention would ultimately be his downfall, and by the following year, detectives had identified the killer as Dennis Rader, a father of two, a Scout leader, and a trusted member of his church council. Rader was the last person anyone suspected of being a sexual sadist serial killer, but once investigators began putting all the puzzle pieces together, it became clear that Rader's family-man persona was just a mask covering the monster beneath. Try our coffee!! - www.CriminalCoffeeCo.com Become a Patreon member -- > https://www.patreon.com/CrimeWeekly Shop for your Crime Weekly gear here --> https://crimeweeklypodcast.com/shop Youtube: https://www.youtube.com/c/CrimeWeeklyPodcast Website: CrimeWeeklyPodcast.com Instagram: @CrimeWeeklyPod Twitter: @CrimeWeeklyPod Facebook: @CrimeWeeklyPod ADS: 1. https://www.HelixSleep.com/CrimeWeekly - Get 27% off sitewide now! Select our podcast after checkout and let them know we sent you! 2. https://www.SKIMS.com - Shop your favorites at SKIMS.com and select our podcast after you order! 3. https://www.SimpliSafe.com/Crimeweekly - Save 60% on a SimpliSafe home security system today! 4. https://www.HungryRoot.com - Use code CRIMEWEEKLY for 40% off your first box, plus a FREE item of your choice in every box FOR LIFE! 5. https://www.FactorMeals.com/CrimeWeekly50Off - Use code CRIMEWEEKLY50OFF for 50% off your first box and FREE breakfast for a year!

Hour 3 opens with Boomer diving into Netflix history docs on James Garfield, which quickly sends Gio into a wild pivot on the BTK killer. From there, attention turns to Jets–Patriots tonight, where Justin Fields is expected to start despite some brutal performances this season. The guys question whether Fields has any future here and discuss the Giants turning to Jameis Winston while Joe Schoen's job status hangs in the balance. Jerry Recco returns with an update featuring Drake Maye ahead of Jets/Pats, more from interim Giants coach Mike Kafka, and Russell Wilson reflecting on close losses under Brian Daboll. Matt LaFleur is asked if he's coaching for his job, Terry Bradshaw questions whether Tom Brady is truly the best, and the Knicks' home streak ends with a loss to the Magic. The crew also debates whether Jerry would move to Memphis for an NBA play-by-play job. The hour closes with Gio needing to stay in NYC for a Dunkin' event, and a caller asking why the Giants' defense looks exhausted late in games.

A loaded Thursday on Boomer & Gio. Hour 1 opens with a tribute to beloved New York hockey writer Larry Brooks, followed by a heated debate on Aaron Glenn's attitude toward the media. Jerry Recco's update includes Mike Kafka's first comments as interim head coach, Brian Burns on whether he let Brian Daboll down, and Jameis Winston fired up to start in “the greatest city in the world.” The guys also hit Russell Wilson's demotion reaction, AJ Brown telling fantasy owners to drop him, the Knicks' loss at MSG, and Scott Boras' alliterative pitch for Pete Alonso. They close the hour with the station's old-school “meet & beat” Giants/Packers promo. Hour 2 breaks down the Disney vs YouTubeTV standoff on earnings day, Gio admitting he watches regular YouTube more than anything else, and more from Mike Kafka, who says he remains tight with Brian Daboll. The crew reacts to Michael Penix Jr. revealing he doesn't have many teammates to lean on during tough days, plus more Knicks reaction and a note that Drew Brees will be on the call for Packers/Giants. Hour 3 starts with Boomer referencing Netflix's James Garfield content before Gio veers into a BTK documentary. The focus shifts to Jets–Patriots tonight with Justin Fields expected to start despite ugly performances. The guys question Fields' future, assess the Giants turning to Jameis, and consider Joe Schoen's job security. Jerry's update features Drake Maye, Mike Kafka, Russell Wilson, and Matt LaFleur answering job-related questions. Terry Bradshaw compares Tom Brady to Otto Graham, the Knicks lose again, and the hour ends with Gio staying in NYC for a Dunkin' event and a caller asking why the Giants' defense looks gassed. Hour 4 begins with stunned callers questioning how the Jets have one takeaway and zero interceptions through nine games. Calls roll in about Kafka's future, Fields vs. Jameis tonight, and Garrett Wilson's status. Jerry's final update hits Stefon Diggs' nor'easter uniforms, Brian Burns' honesty, AJ Brown's fantasy football comments, and more Knicks injury updates. The Moment of the Day is the Giants–Packers “meet & beat” promo. The show wraps with Gio predicting the Jets get crushed — and rooting for it — while Boomer says Thursday night games always stay close.

Boomer dives into Netflix's James Garfield documentaries, Gio abruptly steers things into a BTK killer deep-dive, and then the guys lock in on Jets–Patriots tonight. With Justin Fields expected to start despite some rough outings this season, Boomer & Gio debate what we'll see, what's at stake, and whether Fields has any real future here.

Pai de família, trabalhador e com um cargo importante na sua igreja: essa era a vida tranquila que Dennis Rader aparentava viver. O que ninguém sabia é que, atrás dessa máscara de homem simples, ele escondia sua verdadeira face, a de um assassino cruel, que tinha prazer em torturar suas vítimas e se gabar dos seus crimes para a polícia. Esse é o podcast Clube dos Detetives e hoje nós vamos falar sobre o Dennis Rader, que ficou conhecido como BTK.• VERSÃO ESCRITA:- https://www.podcastcdd.com.br/post/105-dennis-rader-o-btk-serial-killer• APOIE O PODCAST: - Apoia.se: https://apoia.se/clubedosdetetives- PIX: podcastcdd@gmail.com• REDES SOCIAIS:- Site:⁠ ⁠http://www.podcastcdd.com.br⁠⁠- Instagram:⁠ ⁠https://www.instagram.com/podcastcdd/⁠⁠- YouTube: https://www.youtube.com/@podcastcdd- E-mail: podcastcdd@gmail.com• FONTES: BTK Profile: Máscara da Maldade.

In 1974, Wichita, Kansas was shaken by a series of brutal attacks inside family homes. Men, women, and children were bound, tortured, and killed by a predator who called himself BTK. For 17 years, he terrorized the community, claiming at least 10 victims and taunting police with disturbing letters that detailed his crimes. Then in 1991, the killings abruptly stopped, leaving law enforcement and the public to wonder if the killer had vanished forever. For more than a decade, there was silence. Then in 2004, BTK resurfaced with new messages, reigniting fear in Wichita. But that renewed need for attention would ultimately be his downfall, and by the following year, detectives had identified the killer as Dennis Rader, a father of two, a Scout leader, and a trusted member of his church council. Rader was the last person anyone suspected of being a sexual sadist serial killer, but once investigators began putting all the puzzle pieces together, it became clear that Rader's family-man persona was just a mask covering the monster beneath. Try our coffee!! - www.CriminalCoffeeCo.com Become a Patreon member -- > https://www.patreon.com/CrimeWeekly Shop for your Crime Weekly gear here --> https://crimeweeklypodcast.com/shop Youtube: https://www.youtube.com/c/CrimeWeeklyPodcast Website: CrimeWeeklyPodcast.com Instagram: @CrimeWeeklyPod Twitter: @CrimeWeeklyPod Facebook: @CrimeWeeklyPod ADS: 1. https://www.EatIQBAR.com - Text WEEKLY to 64000 for 20% off ALL IQBAR products and FREE shipping! 2. https://www.LiquidIV.com - Use code CRIMEWEEKLY for 20% off your first order! 3. https://www.Rula.com/CrimeWeekly - Take the first steps to better mental health today. After signing up, let them know we sent you! 4. https://www.HelloFresh.com/CrimeWeekly10FM - Use code CRIMEWEEKLY10FM for 10 FREE meals and FREE breakfast for life! 5. https://www.TryFum.com - Use code CRIMEWEEKLY and get a FREE gift with your order!

The story of the hunt for one of the most notorious serial killers in recent American history--the BTK killer, who terrorized the Wichita, Kansas, area for years. After committing at least seven brutal murders, BTK (for Bind, Torture, Kill) vanished for over 25 years before sending clues of his crimes to the media in 2004. He continued to avoid capture until a forensic computer expert traced a computer disc that led investigators to a surprising suspect--a church president.This Episode is sponsored by BetterHelpBetterHelp: Visit BetterHelp.com/COLDCASE to get 10% off your first month.goPure: head to gopurebeauty.com and use code coldcase at checkout for 25% off!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dennis Rader parecía un hombre común, pero detrás de esa fachada se escondía uno de los asesinos seriales más metódicos y perturbadores de Estados Unidos. El hombre que se hacía llamar BTK, mantuvo en jaque a la policía durante tres décadas.En este episodio hablamos de su historia y cómo finalmente su propio ego fue lo que lo llevó a caer.

In 1974, Wichita, Kansas was shaken by a series of brutal attacks inside family homes. Men, women, and children were bound, tortured, and killed by a predator who called himself BTK. For 17 years, he terrorized the community, claiming at least 10 victims and taunting police with disturbing letters that detailed his crimes. Then in 1991, the killings abruptly stopped, leaving law enforcement and the public to wonder if the killer had vanished forever.  For more than a decade, there was silence. Then in 2004, BTK resurfaced with new messages, reigniting fear in Wichita. But that renewed need for attention would ultimately be his downfall, and by the following year, detectives had identified the killer as Dennis Rader, a father of two, a Scout leader, and a trusted member of his church council. Rader was the last person anyone suspected of being a sexual sadist serial killer, but once investigators began putting all the puzzle pieces together, it became clear that Rader's family-man persona was just a mask covering the monster beneath. Try our coffee!! - www.CriminalCoffeeCo.com Become a Patreon member -- > https://www.patreon.com/CrimeWeekly Shop for your Crime Weekly gear here --> https://crimeweeklypodcast.com/shop Youtube: https://www.youtube.com/c/CrimeWeeklyPodcast Website: CrimeWeeklyPodcast.com Instagram: @CrimeWeeklyPod Twitter: @CrimeWeeklyPod Facebook: @CrimeWeeklyPod ADS: 1. Download June's Journey: https://woo.ga/v79wbxd2 - Love solving mysteries of your own? Play June's Journey today! June's Journey is available on iOS and Android mobile devices, as well as on PC. 2. https://www.littlespoon.com/CRIMEWEEKLY50 - Use code CRIMEWEEKLY50 for 50% off your first Little Spoon order! 3. https://www.Quince.com/CRIMEWEEKLY - Get FREE shipping and 365-day returns at Quince!

For over thirty years, Wichita, Kansas lived in fear of a man who called himself BTK — Bind, Torture, Kill. He murdered ten people, including children, and then vanished for years at a time, taunting police and the press with letters that were as cruel as the crimes themselves. But the most disturbing part of this story isn't just the brutality of his murders — it's how Dennis Rader, the man behind BTK, managed to live a perfectly ordinary life right in plain sight. He was a husband. A father. A church council president.A city compliance officer. And behind all of it — a sadistic killer who hid in the open for more than three decades. In this episode of The Redacted Report, we dig into the full story of Dennis Rader — not just the crimes, but the psychology and deception that let him walk unnoticed among his victims' families and his community. We trace his path from a disturbed Kansas kid fascinated by control and bondage to the day he finally slipped — undone by his own arrogance and a floppy disk that revealed his name.You'll hear how Rader meticulously planned each murder, how he craved attention more than anything else, and how his need to be recognized ultimately destroyed him. We revisit the detectives who refused to give up on the cold case, the technological breakthroughs that caught him decades later, and the haunting question that lingers: how does someone capable of such horror look so normal?From his chilling phone calls to the police to his bizarre confessions in court, this is the story of a man who wanted to be remembered — and of the investigators who made sure he would be, but not in the way he imagined.The Redacted Report: BTK – The Killer Next Door pulls back the curtain on one of America's most terrifying killers — and exposes how easily evil can hide behind a familiar smile.

We've got an update on the wounded hawk on Susie's property and an update on the wounded boobs in Susie's body. We hear how her second MRI went, and why she's mad as a hornet. Sarah had a breakdown about her haircut, but we cracked the case on what was really causing it. We debate what song we'd like to hear again for the first time. Susie is continuing her year of lesbian intrigue after she got hit on by a lady at a bar. We learn about the hack some people are using to beat the algorithm of dating apps that intentionally keep you from getting the people you really want for free. Susie discusses the John Candy documentary, why he was such a treasure, and how special it is when a man has a tender heart. We talk about the BTK serial killer documentary, and his relationship with his family. Plus, we welcome Chris Dalla Riva, author of Uncharted Territory: What the Numbers Tell Us About the Biggest Hit Songs and Ourselves, and hear what we can learn from all of the #1 hits in history.Brain Candy Podcast Presents: Susie & Sarah's SpOoOoOoOoktacular Spectacle, October 30, Oriental Theater, Denver, Colorado: Get your tickets! Brain Candy Podcast Website - https://thebraincandypodcast.com/Brain Candy Podcast Book Recommendations - https://thebraincandypodcast.com/books/Brain Candy Podcast Merchandise - https://thebraincandypodcast.com/candy-store/Brain Candy Podcast Candy Club - https://thebraincandypodcast.com/product/candy-club/Brain Candy Podcast Sponsor Codes - https://thebraincandypodcast.com/support-us/Brain Candy Podcast Social Media & Platforms:Brain Candy Podcast LIVE Interactive Trivia Nights - https://www.youtube.com/@BrainCandyPodcast/streamsBrain Candy Podcast Instagram: https://www.instagram.com/braincandypodcastHost Susie Meister Instagram: https://www.instagram.com/susiemeisterHost Sarah Rice Instagram: https://www.instagram.com/imsarahriceBrain Candy Podcast on X: https://www.x.com/braincandypodBrain Candy Podcast Patreon: https://www.patreon.com/braincandy (JOIN FREE - TONS OF REALITY TV CONTENT)Brain Candy Podcast Sponsors, partnerships, & Products that we love:Get $10 off your first month's subscription and free shipping when you go to https://nutrafol.com and enter the promo code BRAINCANDYThis episode is sponsored by BetterHelp. Get 10% off your first month at https://www.betterhelp.com/braincandyHead to https://airdoctorpro.com and use promo code CANDY to get UP TO $300 off today! See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this gripping episode of The Guilty Files Podcast, we go beyond the headlines and dive deep into one of America's most haunting true crime stories — the life and legacy of Dennis Rader, the BTK Killer. “Bind. Torture. Kill.” Three words that held an entire city hostage for more than three decades while a monster disguised himself as an ordinary man.Dennis Rader wasn't the drifter or loner that popular culture paints as a serial killer. He was a husband, a father, a Boy Scout leader, and the council president of his church. By day, he enforced city ordinances in Park City, Kansas, measuring grass heights and citing residents for leaving trash cans out too early. By night, he fed a sadistic fantasy life that would claim ten lives and terrorize an entire community. His obsession with control and his ability to mask it behind a façade of normalcy made him one of the most chilling killers in modern history.This episode traces Rader's story from his early years in Pittsburg, Kansas — where his fascination with bondage and cruelty took root — to his years of military service, marriage, and eventual descent into a life of hidden predation. We explore how his childhood acts of animal torture and fetishism went unrecognized as red flags, how he weaponized his day jobs at ADT Security and as a municipal compliance officer to study his victims, and how his twisted need for power became ritualized in his killings.We follow the trajectory of BTK's crimes, beginning with the horrifying Otero family murders in 1974 and continuing through his series of killings that left Wichita living in fear. We unpack the infamous letters, poems, and packages that he sent to police and the media — the communications that transformed the murders into a decades-long psychological game. We also examine the eerie fourteen-year period of silence where Rader appeared to vanish, though he was in fact living quietly among the very people who feared him most.From his eventual return to taunting law enforcement in 2004, to the digital blunder that led to his downfall — a single floppy disk containing traceable metadata — this episode brings listeners inside the meticulous investigation that finally unmasked BTK.You'll hear how decades-old DNA from the Otero crime scene and a sample taken from Rader's daughter's medical record closed one of America's most elusive cold cases.We break down the courtroom confession that stunned the nation, where Rader clinically detailed each murder with chilling composure. We highlight the courage of survivors and the families of victims like Charlie Otero, who has carried the weight of trauma since discovering his family's murder at age fifteen. We also look at the profound role of forensic innovation and patience — how careful evidence preservation and evolving DNA technology turned a forgotten case file into the key that finally locked BTK away for good.Beyond the crimes, this episode delves into the mind of Dennis Rader — a study in compartmentalization, ego, and deviance.We examine how he managed to separate “Dennis the family man” from “BTK the killer,” why he craved recognition more than escape, and what his case reveals about the psychology of control. We also confront the unanswered questions: Were there more victims? How did he suppress his urges for years at a time? And how does someone who claims to love his family justify the systematic destruction of others?Finally, we explore the aftermath: Rader's life inside the El Dorado Correctional Facility, where he remains in protective custody and continues to seek attention through letters and interviews. We discuss his daughter Kerri Rawson's memoir, A Serial Killer's Daughter, her path toward healing, and the broader impact of the BTK case on law enforcement and society's understanding of how ordinary evil hides in plain sight. The Guilty Files delivers not just the crimes, but the psychology, the investigation, and the enduring questions that still surround Dennis Rader. This is more than a true crime story — it's a chilling reminder that the most dangerous predators can look just like us, and that justice sometimes depends on the details we refuse to ignore.

C-Lane joins us as Producer today for a shortened show, courtesy of Monday Night Football, and we kick things off by talking about what we did over the weekend as everyone gears up for Halloween. Next up is JCS News, followed by Jim sharing some exciting news about how to help reduce allergies in children. After that we talk about some starting statistics about preschoolers and toddlers and how often they go outside to play. We then talk about the Supreme Court weighing whether a federal law that bars drug users from having guns violates the second amendment. After that, we talk about a new creme created to help women with their libido before tackling a new documentary about the serial killer BTK. Trivia is next before we wrap everything up for a Monday.

C-Lane joins us as Producer today for a shortened show, courtesy of Monday Night Football, and we kick things off by talking about what we did over the weekend as everyone gears up for Halloween. Next up is JCS News, followed by Jim sharing some exciting news about how to help reduce allergies in children. After that we talk about some starting statistics about preschoolers and toddlers and how often they go outside to play. We then talk about the Supreme Court weighing whether a federal law that bars drug users from having guns violates the second amendment. After that, we talk about a new creme created to help women with their libido before tackling a new documentary about the serial killer BTK. Trivia is next before we wrap everything up for a Monday. See omnystudio.com/listener for privacy information.

IDM gives its take on how well Netflix is depicting gruesome murders these days (Ed Gein and BTK reviews). An intriguing new trailer suggests the U.S. gov't may be ready to co-sign UFO conspiracies. Is Shorts ready to budge on his anti-alien stance (no politics)?

Losers Randall Colburn and Michael Roffman head to Hollywood King again to discuss the latest developments in King's Dominion, specifically The Running Man, Rat, BTK, Chain Reactions, and more. They also dive into tweets, threads, and blues -- from "bad" King movies to King's favorite movies of all time. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dennis Rader, plus connu sous les trois initiales BTK avec lesquelles il signait ses meurtres. B comme Bind, attacher; T comme Torture, torturer; K comme Kill, tuer. Au moins dix meurtres, des femmes essentiellement, ligotées et exécutées. Il tuait puis envoyait des lettres et des poèmes. Pendant trois décennies, BTK, a défié la police américaine. Retrouvez tous les jours en podcast le décryptage d'un faits divers, d'un crime ou d'une énigme judiciaire par Jean-Alphonse Richard, entouré de spécialistes, et de témoins d'affaires criminelles.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dennis Rader, plus connu sous les trois initiales BTK avec lesquelles il signait ses meurtres. B comme Bind, attacher; T comme Torture, torturer; K comme Kill, tuer. Au moins dix meurtres, des femmes essentiellement, ligotées et exécutées. Il tuait puis envoyait des lettres et des poèmes. Pendant trois décennies, BTK, a défié la police américaine. Retrouvez tous les jours en podcast le décryptage d'un faits divers, d'un crime ou d'une énigme judiciaire par Jean-Alphonse Richard, entouré de spécialistes, et de témoins d'affaires criminelles.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

From Ed Gein and Ted Bundy, to BTK and Jeffrey Dahmer, Criminologist Dr. Katherine Ramsland has spent the last 30 years studying serial killers - trying to find out what drives them to kill. We talk the mind of a serial killer, the worst serial killers you've never heard of and why we're fascinated by them. Then, we countdown the Top 5 Worst Sports Cities Dr. Katherine Ramsland: 01:11 Pointless: 33:40 Top 5 Worst Sports Cities: 55:00 Contact the Show Dr. Katherine Ramsland Website Dr. Katherine Ramsland Facebook Learn more about your ad choices. Visit megaphone.fm/adchoices

On January 15, 1974, 15-year-old Charlie Otero and his siblings came home in Wichita, Kansas, to find their family murdered — the first known victims of the BTK killer: Bind, Torture, Kill. Dennis Rader, a father, church leader, and city worker, hid in plain sight while terrorising a community for decades. After years of taunting the police, he was finally caught in 2005. His daughter, Kerri Rawson, later shared her story. In the new Netflix documentary My Father the BTK Killer, director Skye Borgman explores Kerri’s journey. She also directed Unknown Number, about Kendra Licari — the mother who anonymously harassed her own daughter online for nearly a year. Skye joins us to talk about both disturbing true crime stories. Watch My Father, the BTK Killer here and Unknown Number: The High School Catfish here. CREDITS Guest: Skye Borgman Host: Claire Murphy Senior Producer: Tahli Blackman Group Executive Producer: Ilaria Brophy Audio Producer: Jacob Round GET IN TOUCH Follow us on Instagram and TikTok @truecrimeconversations Make sure to leave us a rating and review on Apple & Spotify to let us know how you're liking the episodes. Want us to cover a case on the podcast? Email us at truecrime@mamamia.com.au or send us a voice note. If any of the contents in this episode have caused distress, know that there is help available via Lifeline on 13 11 14 or Beyond Blue on 1300 22 4636. We acknowledge the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures.Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

#WHATSHAPPENING: Newsom Fire Fighters, Kaiser Strike, Trump and Charlie Kirk Award, RIP D'Angelo. Brigida Dagostino Lost Job Due to A.I! True Crime Tuesday: BTK Killer   

Gary and Shannon discuss the BTK Killer and a new documentary focusing on his daughters experince out on Netflix.

Criada por un hombre que llevaba una monstruosa doble vida, la hija del asesino en serie BTK comparte su escalofriante historia.

A short review, because I just watched Netflix's "My Father, the BTK Killer" and I need to talk about it.This isn't another documentary glorifying a serial killer. This is Kerri Rawson's story. She's the daughter of Dennis Rader, the BTK killer who murdered 10 people over nearly two decades while pretending to be a normal dad.Imagine finding out your Boy Scout leader father, who danced with you to John Denver and took you on family vacations, is one of America's most notorious serial killers. That's Kerri's reality. And 20 years later, she's still processing it.This show hit...differently. Because it's not about him. It's about the wreckage he left behind. The family trying to make sense of the senseless. The daughter asking herself how she didn't see the monster living in her house.Become a supporter of this podcast: https://www.spreaker.com/podcast/we-saw-the-devil-a-true-crime-podcast--4433638/support.Website: http://www.wesawthedevil.comPatreon: http://www.patreon.com/wesawthedevilDiscord: https://discord.gg/X2qYXdB4Twitter: http://www.twitter.com/WeSawtheDevilInstagram: http://www.instagram.com/wesawthedevilpodcast.

When Vicki Wegerle, the mother of two young children, was strangled in Wichita, Kansas, in 1986, her husband Bill was considered by many to be the prime suspect. For the next 18 years, police lacked evidence to charge Bill, or anyone else with Vicki's murder. Subsequently, a desire for recognition led Dennis Rader, aka the BTK (bind, torture, kill) killer, to fall into a police trap and supply them with incriminating evidence. This classic "48 Hours" episode last aired on 10/1/2005. Watch all-new episodes of “48 Hours” on Saturdays, and stream on demand on Paramount+. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

For decades, allergists have focused on blocking what happens outside the mast cell: histamine, IgE, and interleukins. But now, there's a new way to stop allergic inflammation before it even starts: by targeting what happens inside the cell with BTK Inhibitors. Dr. Payel Gupta and Kortney are joined by Dr. Matthew Giannetti to unpack what BTK actually does and why inhibiting it represents an exciting breakthrough in allergy and immunology. Together, they explore how BTK inhibitors work, why this inside-the-cell approach is different from anything before, and what it could mean for people living with chronic spontaneous urticaria (CSU). What the episode covers about BTK inhibitors: BTK explained: Bruton's tyrosine kinase is a pivotal “last step” before mast-cell degranulation. How BTK inhibitors work: Blocking BTK can stop histamine release downstream of many outside triggers. The science: Why BTK binding is irreversible for each molecule and how the body “re-makes” BTK over time. Safety in brief: A look at petechiae (small pinpoint spots), what to monitor, and how shared decision-making guides treatment choices. The future of BTK inhibitors: Exploring their potential role in other allergic conditions.    ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Welcome to the 6th episode of our BTK/ASGBI series!  During this series, BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam will compare and contrast various aspects of surgery between the United States and the United Kingdom, debating who does what better.  In this episode, we delve into surgical training, current challenges, and hopes for the future of surgical training in the US and the UK. We will be discussing the advent of the EPA curriculum in the US, the current challenge of obtaining a speciality position in the UK, and tips for making the resident to attending/junior faculty transition smoothly. Dr. Jeremy Lipman represents the US while Dr. Phil Pearce represents the UK in this thought-provoking conversation. Dr. Lipman is a colorectal surgeon at the Cleveland Clinic and the director of graduate medical education for all training programs at the Cleveland Clinic. Additionally, he is an Associate Dean for Graduate Medical Education and Professor of Surgery at Case Western Reserve University. He is passionate about surgical training and holds the James E. Sampliner Endowed Chair in Surgical Education.  Dr. Phil Pearce is a consultant in emergency general surgery in Oxford with interests in trauma, complex biliary disease, and most importantly a passion for training. Take a listen and let us know what you think- who does surgical education and training better?  References: Speciality training position in the NHS https://www.ft.com/content/e4b364c3-6a20-42ee-a9a5-ab9eea441c87?utm_source=chatgpt.com https://www.theguardian.com/society/2025/jul/02/nhs-in-england-told-to-slash-recruitment-of-overseas-trained-medics?utm_source=chatgpt.com Surgery job market in the US https://surgpli.com/the-state-of-surgery-as-a-career-in-2025/ EPA curriculum https://www.aamc.org/about-us/mission-areas/medical-education/cbme/core-epas Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In the second episode of this new collaboration between BTK and Annals of surgery, we discuss another hot topic: academic surgery. Specifically, we discuss dedicated research time for residents and how surgical leaders think about building the academic surgery enterprise. This discussion was inspired by a couple of recent papers in Annals of Surgery that stirred up a lot of conversation on social media which can be found below.  Host: Cody Mullens, MD MPH — general surgery resident at University of Michigan current BTK Surgery Education Fellow (@Cody_Mullens) Guest: Justin Dimick, MD MPH — Fredrick A Coller Distinguished Professor and Chair of Surgery at the University of you Michigan and Editor in Chief at Annals of Surgery (@jdimick1) Papers:  Career Trajectory After General Surgery Residency Do Academic Program Graduates Pursue Academic Surgery? https://journals.lww.com/annalsofsurgery/abstract/2025/05000/career_trajectory_after_general_surgery_residency_.10.aspx Training the Surgeon-scientist: Time (and Money) Well Spent? https://journals.lww.com/annalsofsurgery/citation/9900/training_the_surgeon_scientist__time__and_money_.1318.aspx Introducing a New Annals of Surgery Section Professional Development for the Contemporary Surgeon https://journals.lww.com/annalsofsurgery/fulltext/2025/08000/introducing_a_new_annals_of_surgery_section_.8.aspx Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen BTK Fan Favorites:  General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US